Todos os posts
Recomendações para o sequenciamento total do genoma no diagnóstico de doenças raras.
30 Mai, 2022 | 12:46hEstudo randomizado | Eficácia e segurança do uso de pazopanibe com TRC105 vs. pazopanibe isolado para tratamento de pacientes com angiossarcoma avançado.
30 Mai, 2022 | 12:45hComentários:
Addition of Carotuximab to Pazopanib in Advanced Angiosarcoma – The ASCO Post
Comentários no Twitter
A phase III trial in 123 patients with advanced-stage angiosarcoma reveals no significant difference in mPFS with pazopanib plus the anti-endoglin (CD105) mAb carotuximab vs pazopanib alone: https://t.co/TPPFRNCOoC #scmsm #caxtx
— NatureRevClinOncol (@NatRevClinOncol) April 5, 2022
First randomized trial in angiosarcoma demonstrates no signif difference in progression-free survival for combo of novel angiogenesis inhibitor carotuximab + pazopanib vs. pazopanib alone in advanced angiosarcoma. https://t.co/f1Z5EjOdK2 pic.twitter.com/qf3Tez9VU2
— JAMA Oncology (@JAMAOnc) March 31, 2022
Estudo randomizado | Tiragolumabe com atezolizumabe vs. placebo com atezolizumabe como tratamento de primeira linha para câncer de pulmão de não pequenas células com expressão de PD-L1.
30 Mai, 2022 | 12:44hTiragolumab plus atezolizumab versus placebo plus atezolizumab as a first-line treatment for PD-L1-selected non-small-cell lung cancer (CITYSCAPE): primary and follow-up analyses of a randomised, double-blind, phase 2 study – The Lancet Oncology (link para o resumo – $ para o texto completo)
Comentário: First-line tiragolumab–atezolizumab promising for PD-L1-positive advanced NSCLC – Medicine Matters
Estudo randomizado | Adebrelimabe ou placebo com carboplatina e etoposídeo como tratamento de primeira linha para câncer de pulmão de pequenas células em estágio extenso.
30 Mai, 2022 | 12:40hAdebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial – The Lancet Oncology (link para o resumo – $ para o texto completo)
Principais estudos de 2021 relevantes para a atenção primária.
27 Mai, 2022 | 13:47hTop studies of 2021 relevant to primary care: From the PEER team – Canadian Family Physician
Estudo relata primeiro uso de antivirais em pacientes com varíola dos macacos.
27 Mai, 2022 | 13:45hComunicado de imprensa: Study reports first use of antivirals in monkeypox patients – Lancet
Estudo original: Clinical features and management of human monkeypox: a retrospective observational study in the UK – The Lancet Infectious Diseases
Comentário: Antiviral drug may limit monkeypox symptom duration, infectiousness – CIDRAP
Comentário de um dos autores no Twitter (fio – clique para saber mais)
Clinical features and management of human monkeypox: a retrospective observational study in the UK https://t.co/0nUtw3lEDn
— Jake Dunning (@OutbreakJake) May 24, 2022
Comentário de estudo | Grande estudo mostra que risco de COVID longa diminui apenas discretamente após a vacinação.
27 Mai, 2022 | 13:44hComentário: Long COVID risk falls only slightly after vaccination, huge study shows – Nature
Estudo original: Long COVID after breakthrough SARS-CoV-2 infection – Nature Medicine
Comentário do autor no Twitter (fio – clique para saber mais)
The latest from our team in @NatureMedicine
Does vaccination protect from #LongCovid?
Vaccines modestly reduce but do not eliminate risk of Long Covid @VAResearch @vahsrd @WUSTLmed @WUSTLnews @VREFSTL@Biostayan @BCBowe https://t.co/UEexmL8svS
A thread 🧵
— Ziyad Al-Aly, MD (@zalaly) May 25, 2022
Estudo de coorte | Trajetória dos sintomas de Covid longa após vacinação contra Covid-19.
27 Mai, 2022 | 13:41hTrajectory of long covid symptoms after covid-19 vaccination: community based cohort study – The BMJ
Editorial: Are vaccines a potential treatment for long covid? – The BMJ
Comunicado de imprensa: Vaccination after SARS-CoV-2 infection linked to a decrease in long covid symptoms – BMJ Newsroom
Comentário no Twitter
LONG COVID: Number of well controlled studies (controls means comparison group of 1) unvaccinated and 2) those who have never had COVID) that show vaccination works to reduce or eliminate long COVID symptoms increasing. BMJ below + biggest from Israel herehttps://t.co/jtZ6aoDmFA https://t.co/n5oDs0Zxe9
— Monica Gandhi MD, MPH (@MonicaGandhi9) May 19, 2022
Estudo de coorte | Proteção e queda da imunidade natural e híbrida ao SARS-CoV-2.
27 Mai, 2022 | 13:39hProtection and Waning of Natural and Hybrid Immunity to SARS-CoV-2 – New England Journal of Medicine
Editorial: Audio Interview: Waning Immunity against Covid-19
Comentário no Twitter
Protection against SARS-CoV-2 waned over time in both vaccinated and previously infected persons; an additional vaccine dose restored protection, find investigators from Israel. https://t.co/617uBmWu8l pic.twitter.com/yiDnBbCuQ5
— NEJM (@NEJM) May 25, 2022